Bond Digital Health has initiated an exciting new technology development and commercialisation
partnership project with Imspex Diagnostics Ltd.
The two Wales-based specialist Life Sciences companies will combine Imspex’s ‘early warning systems’ for healthcare using its proprietary gas chromatography (GC) and Ion Mobility Spectrometry (IMS) technology and Bond’s proprietary Transform® platform, a real-time data capture and management system for diagnostic tests.
Imspex Diagnostics Ltd was founded in 2011, delivering unique technology with combined gas chromatography (GC) and Ion Mobility Spectrometry (IMS) which delivers fast, accurate detection and diagnosis for an extremely broad range of global healthcare applications. Acquiring the analytics expert G.A.S. mbH in 2013 places them as experts in the field of Volatile Organic Compounds (VOCs) with the capability to provide quality and contamination solutions for manufacturing and end-products for a range of blue-chip companies, world leading hospitals, research centres and universities. Imspex continues to expand the boundaries of VOC detection, developing their leadership position and capability to provide innovative solutions to the healthcare market.
Bond Digital Health is unique in that it’s the only company in the world offering bespoke digital products and services specifically for lateral flow devices. Digitising an entire industry, assisting with the global effort to decentralise health screening, Bond has developed their own white label platform for lateral flow technologies, called Transform®. The platform features app development, cloud data management, real-time analytics dashboard and offers cloud connectivity. Transform® is compliant with medical device software regulations and is fully regulated.
Of the partnership, Bond’s Commercial Director Phil Groom said: “We’re thrilled to be partnering
with Imspex and to be working on an exciting project with a pioneering company. We look forward
to sharing more information on the partnership and the project early in 2022.”
Imspex’s Founder and chairman, Santi Dominguez, said: “This is an exciting project and combines
two leading technologies to provide data capture, research and faster diagnosis by clinicians leading
to better patient outcomes.”
The partnership will benefit the healthcare industry hugely when it comes to diagnostic testing with Bond already supporting the fight against Covid-19, currently powering three in-market rapid lateral flow tests in the UK, USA and Canada. They have ambitious plans to develop their world-leading platform further with smartphone reader integration, multi-language support plus the ability to sort, filter and export your data. This combined with the cutting edge technology of Imspex who have honed their collective high-end chemistry analytics expertise is sure to go from strength-to-strength.